Literature DB >> 24599533

Direct neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrV.

Maya I Ivanov1, Jim Hill, James B Bliska.   

Abstract

Plague is an acute infection caused by the Gram-negative bacterium Yersinia pestis. Antibodies that are protective against plague target LcrV, an essential virulence protein and component of a type III secretion system of Y. pestis. Secreted LcrV localizes to the tips of type III needles on the bacterial surface, and its function is necessary for the translocation of Yersinia outer proteins (Yops) into the cytosol of host cells infected by Y. pestis. Translocated Yops counteract macrophage functions, for example, by inhibiting phagocytosis (YopE) or inducing cytotoxicity (YopJ). Although LcrV is the best-characterized protective antigen of Y. pestis, the mechanism of protection by anti-LcrV antibodies is not fully understood. Antibodies bind to LcrV at needle tips, neutralize Yop translocation, and promote opsonophagocytosis of Y. pestis by macrophages in vitro. However, it is not clear if anti-LcrV antibodies neutralize Yop translocation directly or if they do so indirectly, by promoting opsonophagocytosis. To determine if the protective IgG1 monoclonal antibody (MAb) 7.3 is directly neutralizing, an IgG2a subclass variant, a deglycosylated variant, F(ab')2, and Fab were tested for the ability to inhibit the translocation of Yops into Y. pestis-infected macrophages in vitro. Macrophage cytotoxicity and cellular fractionation assays show that the Fc of MAb 7.3 is not required for the neutralization of YopJ or YopE translocation. In addition, the use of Fc receptor-deficient macrophages, and the use of cytochalasin D to inhibit actin polymerization, confirmed that opsonophagocytosis is not required for MAb 7.3 to neutralize translocation. These data indicate that the binding of the variable region of MAb 7.3 to LcrV is sufficient to directly neutralize Yop translocation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599533      PMCID: PMC4018875          DOI: 10.1128/CVI.00013-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  47 in total

Review 1.  Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen).

Authors:  Robert R Brubaker
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

Review 2.  Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function.

Authors:  David G Thanassi; James B Bliska; Peter J Christie
Journal:  FEMS Microbiol Rev       Date:  2012-05-24       Impact factor: 16.408

3.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

Review 4.  The type III secretion system tip complex and translocon.

Authors:  C A Mueller; P Broz; G R Cornelis
Journal:  Mol Microbiol       Date:  2008-04-08       Impact factor: 3.501

5.  Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury.

Authors:  T Sawa; T L Yahr; M Ohara; K Kurahashi; M A Gropper; J P Wiener-Kronish; D W Frank
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

6.  IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri.

Authors:  Marianela Espina; Andrew J Olive; Roma Kenjale; David S Moore; S Fernando Ausar; Robert W Kaminski; Edwin V Oaks; C Russell Middaugh; William D Picking; Wendy L Picking
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

7.  The ability to replicate in macrophages is conserved between Yersinia pestis and Yersinia pseudotuberculosis.

Authors:  Céline Pujol; James B Bliska
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

8.  Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.

Authors:  Nicholas A Eisele; Deborah M Anderson
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

9.  Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge.

Authors:  Carolina Sofer-Podesta; John Ang; Neil R Hackett; Svetlana Senina; David Perlin; Ronald G Crystal; Julie L Boyer
Journal:  Infect Immun       Date:  2009-01-05       Impact factor: 3.441

10.  Function and molecular architecture of the Yersinia injectisome tip complex.

Authors:  Petr Broz; Catherine A Mueller; Shirley A Müller; Ansgar Philippsen; Isabel Sorg; Andreas Engel; Guy R Cornelis
Journal:  Mol Microbiol       Date:  2007-09       Impact factor: 3.501

View more
  8 in total

1.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

2.  Antibody Opsonization Enhances Early Interactions between Yersinia pestis and Neutrophils in the Skin and Draining Lymph Node in a Mouse Model of Bubonic Plague.

Authors:  Jeffrey G Shannon; B Joseph Hinnebusch
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

Review 3.  Immunomodulatory Yersinia outer proteins (Yops)-useful tools for bacteria and humans alike.

Authors:  Benjamin Grabowski; M Alexander Schmidt; Christian Rüter
Journal:  Virulence       Date:  2017-03-15       Impact factor: 5.882

4.  A Capsular Polysaccharide-Specific Antibody Alters Streptococcus pneumoniae Gene Expression during Nasopharyngeal Colonization of Mice.

Authors:  Christopher R Doyle; Jee-Young Moon; Johanna P Daily; Tao Wang; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

Review 5.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 6.  Potential human immunotherapeutics for plague.

Authors:  Voahangy Andrianaivoarimanana; Lovasoa Nomena Randriantseheno; Kristoffer M Moore; Nicola J Walker; Steven G Lonsdale; Sarah Kempster; Neil A Almond; Minoarisoa Rajerison; E Diane Williamson
Journal:  Immunother Adv       Date:  2021-10-05

Review 7.  Antibodies Inhibiting the Type III Secretion System of Gram-Negative Pathogenic Bacteria.

Authors:  Julia A Hotinger; Aaron E May
Journal:  Antibodies (Basel)       Date:  2020-07-27

Review 8.  Antibiotic Therapy of Plague: A Review.

Authors:  Florent Sebbane; Nadine Lemaître
Journal:  Biomolecules       Date:  2021-05-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.